LL-37 (Cathelicidin) vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | Sermorelin |
|---|---|---|
| Dose Range | 500 mcg–1.6 mg | 100 mcg–300 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 8–12 weeks |
| Route | topical | subcutaneous |
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
What They Have in Common
LL-37 (Cathelicidin), Sermorelin are both commonly used for:
Key Differences
Unique to Sermorelin:
Which Has Stronger Evidence?
| Goal | LL-37 (Cathelicidin) | Sermorelin |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
LL-37 (Cathelicidin)
- Cathelicidin LL-37 Expression in Human Breast Implant Capsules.
Plastic and reconstructive surgery, 2024
- Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Biomedicine hub, 2024
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.
World journal of microbiology & biotechnology, 2023
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?